Spots Global Cancer Trial Database for ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Official Title: ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Study ID: NCT05245760
Study Description
Brief Summary: This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
Detailed Description: Esophageal cancer patients in this trial will receive chemoradiation therapy with tislelizumab, which is an anti-PD-1 antibody, before surgery. Patient will be evaluated for complete pathological response or major pathological response rate following chemoradiation. Patient will continue on to get tislelizumab after surgery to complete total of a year of treatment. They will be evaluated for PFS and OS. Throughout the study, drug tolerability and toxicities will be monitored.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Kentucky, Lexington, Kentucky, United States
Contact Details
Name: Zhonglin Hao, MD, PhD
Affiliation: University of Kentucky
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
